Exclusive Summary

• The extremely mature, patent-free status guarantees absolutely zero IP litigation risks, making it an ideal candidate for rapid distribution penetration in emerging LATAM, SEA, MENA, and CIS regions.
• Backed by solid clinical demand, it effectively targets the psychomotor agitation in 55 million global dementia patients, withdrawal syndrome in 283 million alcohol-dependent individuals, and pediatric Tourette's.
• Characterized by outstanding safety with a distinctively low rate of Extrapyramidal Symptoms (EPS), establishing it as a highly recommended 1st- and 2nd-line treatment in various international clinical guidelines.
• Accelerates local market entry by providing full English CTD-formatted dossiers and rigorous international GMP assurances, drastically reducing MA (Marketing Authorization) approval timelines for overseas partners.
• Harnesses China's ultra-efficient API-FDF FDF supply chain to offer crushing cost advantages, granting local distributors exceptional profit margins and dominant pricing power in public hospital tenders.